Mira Liu, a postdoctoral fellow at Mount Sinai's BioMedical Engineering and Imaging Institute, has developed an MRI method that can predict which patients will develop chronic kidney disease after surgery to remove kidney tumors—offering doctors a glimpse into organ function before the scalpel ever touches skin. The work earned Liu the prestigious W.S. Moore Award for Original Clinical Research at the 2026 International Society for Magnetic Resonance in Medicine annual meeting, recognition that spotlights an emerging frontier in precision medicine: using advanced imaging not just to map anatomy, but to decode how hard an organ is already working to stay healthy.
The challenge Liu addressed is both urgent and deeply personal. Nephrectomy—surgical removal of part or all of a kidney—can be lifesaving for patients with kidney tumors, yet some face a troubling trade-off: reduced kidney function afterward. Currently, physicians have limited tools to predict which patients will be vulnerable to long-term complications. A patient's kidney function might appear normal before surgery, yet deteriorate significantly in the year after, sometimes progressing to chronic kidney disease. That uncertainty leaves doctors and patients navigating treatment decisions in the dark.
In her pilot study, Liu and her team scanned 43 patients with advanced multiparametric MRI before surgery, then tracked their kidney function for a year. The scans evaluated kidney blood flow, oxygen utilization, inflammation, filtration, and microscopic tissue characteristics—a vastly richer picture than standard clinical imaging provides. When researchers compared these MRI measurements against kidney function one year later, a striking pattern emerged: the imaging data could help identify which patients would experience decline or develop chronic kidney disease. Even more significant, combining MRI-derived biomarkers with standard blood tests and clinical assessments dramatically improved risk prediction.
The insight Liu emphasizes is quietly profound: "What makes this work especially exciting is that it suggests MRI may reveal how hard the kidneys are already working to maintain healthy function before surgery takes place," she says. "That hidden stress may help explain why some patients are more vulnerable to kidney disease afterward, even when their kidney function initially appears normal." In other words, an organ that looks fine on paper might actually be straining to compensate for underlying damage invisible to conventional assessment.
Dr. Octavia Bane, Liu's co-mentor at Mount Sinai, frames the broader significance: "By combining advanced MRI with clinical information, we may eventually be able to better personalize treatment plans, monitor high-risk patients more closely, and help protect long-term kidney health." The researchers are careful to emphasize that their work does not suggest patients should avoid kidney cancer surgery. Rather, the goal is to identify which patients might benefit from additional kidney-protective strategies and closer monitoring after treatment—transforming surgery from a one-size-fits-all intervention into a tailored plan.
Liu's published work in the Journal of Magnetic Resonance Imaging represents a shift in how medicine thinks about imaging itself. Rather than serving as a snapshot of what is, quantitative MRI becomes a tool for understanding what might be, offering physicians the foresight to act preventively. For patients facing kidney tumor surgery, that clarity could mean the difference between losing kidney function slowly to the shadows, or stepping into the operating room with eyes wide open.